Retinoic acid down-regulates the expression of the vasoactive intestinal polypeptide receptor type-1 in human breast carcinoma cell lines

Cancer Research

Volumn 58, Issue 21, 1998, Pages 4845-4850

  Madsen, Bente ^a   Georg, Birgitte ^a   Vissing, Henrik ^b   Fahrenkrug, Jan ^a  

^a BISPEBJERG HOSPITAL   (Denmark)

^b NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOHEXIMIDE; DACTINOMYCIN; MESSENGER RNA; RECEPTOR SUBTYPE; RETINOIC ACID; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR;

ARTICLE; BREAST CARCINOMA; CARCINOMA CELL; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN SYNTHESIS; TRANSCRIPTION TERMINATION; TUMOR CELL LINE;

BASE SEQUENCE; BINDING SITES; BREAST NEOPLASMS; CLONING, MOLECULAR; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MOLECULAR SEQUENCE DATA; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; RECEPTORS, VASOACTIVE INTESTINAL POLYPEPTIDE, TYPE I; RNA, MESSENGER; TRETINOIN; TUMOR CELLS, CULTURED;

EID: 0032212489     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Hœgerstrand, A., Jonzon, B., Dalsgaard, C-J., and Nilsson, J. Vasoactive intestinal polypeptide stimulates cell proliferation and adenylate cyclase activity of cultured human keratinocytes. Proc. Natl. Acad. Sci. USA, 86: 5993-5996, 1989.
2. Jiang, S., Kopras, E., McMichael, M., Bell, R. H., Jr., and Ulrik, C. D., II. Vasoactive intestinal peptide (VIP) stimulates in vitro growth of VIP-1 receptor bearing human pancreatic adenocarcinoma-derived cells. Cancer Res., 57: 1475-1480, 1997.
3. Gozes, Y., and Brenneman, D. E. VIP molecular biology and neurobiological function. Mol. Neurobiol, 3: 201-236, 1989.
4. Pincus, W. D., DiCicco-Bloom, E. M., and Black, I. B. Vasoactive intestinal peptide regulates mitosis, differentiation and survival of cultured sympathetic neuroblasts. Nature (Lond.), 343: 564-567, 1990.
5. Wollman, Y., Lilling, G., Goldstein, M. N., Fridkin, M., and Gozes, I. Vasoactive intestinal peptide. A growth promoter in neuroblastoma cells. Brain Res., 624: 339-341, 1993.
6. Fahrenkrug, J. Transmitter role of vasoactive intestinal peptide. Pharmacol. Toxicol., 72: 354-363, 1993.
7. Werner, H., Koch, Y., Fridkin, M., Fahrenkrug, J., and Gozes, I. High levels of vasoactive intestinal peptide in human milk. Biochem. Biophys. Res. Commun., 133: 228-232, 1985.
8. Eriksson, M., Lindh, B., Uvnäs-Moberg, K., and Hökfelt, T. Distribution, and origin of peptide-containing nerve fibres in the rat and human mammary gland. Neuroscience, 70: 227-245, 1996.
9. Berthon, P., Mirossay, L., Ito, S., Calvo, F., and Gespach, C. Functional expression of VIP receptors in normal immortalized and transformed mammary epithelial cells. Life Sci., 50: 791-798, 1992.
10. Scholar, E. M., and Paul, S. Stimulation of tumor cell growth by vasoactive intestinal peptide. Cancer (Phila.), 67: 1561-1564, 1991.
11. Zia, H., Hida, T., Jakowlew, S., Birrer, M., Gozes, Y., Reubi, J. C., Fridkin, M., Gozes, I., and Moody, T. W. Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist. Cancer Res. 56: 3486-3489, 1996.
12. Couvineau, A., Rouyer-Fessard, C., Darmoul, D., Maoret, J-J., Carrero, I., Ogier-Denis, E., and Laburthe, M. Human intestinal VIP receptor: cloning and functional expression of two cDNA proteins with different N-terminal domains. Biochem. Biophys. Res. Commun., 200: 769-776, 1994.
13. Sreedharan, S. P., Patel, D. R., Huang, J-X., and Goetzl, E. J. Cloning and functional expression of a human neuroendocrine vasoactive intestinal peptide receptor. Biochem. Biophys. Res. Commun., 193: 546-553, 1993.
14. Svoboda, M., Tastenoy, M., Van Rampelbergh, J., Goossens, J-F., De Neef, P., Waelbroeck, M., and Robberecht, P. Molecular cloning and functional characterization of a human VIP receptor from sup-T1 lymphoblasts. Biochem. Biophys. Res. Commun., 205: 1617-1624, 1994.
15. Reubi, J. C. In vitro identification of vasoactive intestinal peptide receptors in human tumors: implication for tumor imaging. J. Nucl. Med., 36: 1846-1853, 1995.
16. Waschek, J. A., Richards, M. L., and Bravo, D. T. Differential expression of VIP/PACAP receptor genes in breast, intestinal, and pancreatic cell lines. Cancer Lett., 92: 143-149, 1995.
17. Kester, H. A., van der Leede, B., van der Saag, P. T., and van der Burg, B. Novel progesterone target genes identified by an improved differential display technique suggest that progestine-induced growth inhibition of breast cancer cells coincides with enhancement of differentiation. J. Biol. Chem., 272: 16637-16643, 1997.
18. Moon, R. C., and Metha, R. G. Chemoprevention of mammary cancer by retinoids. Basic Life Sci., 52: 213-224, 1990.
19. Bollag, W., and Holdener, E. E. Retinoids in cancer prevention, and therapy. Ann. Oncol., 3: 513-526, 1992.
20. Hong, W. K., and Itri, L. M. Retinoids, and human cancer. In: M. B. Sporn, A. B. Roberts, and D. S. Goodmann (eds.), The Retinoids, pp. 631-659. New York: Raven Press, 1994.
21. Sporn, M. B., and Roberts, A. B. Role of retinoids in differentiation and carcinogenesis (Lond.). Cancer Res., 43: 3034-3040, 1983.
22. Fitzgerald, P., Teng, M., Chandraratna, A. S., Heyman, R. A., and Allegretto, E. A. Retinoic acid receptor α expression correlates with retinoid-induced growth inhibition of human breast cancer cells regardless of estrogen receptor status. Cancer Res., 37: 2642-2650, 1997.
23. Mangelsdorf, D. J., Umesono, K., and Evans, R. M. The retinoid receptors. In: M. B. Sporn, A. B. Roberts, and D. S. Goodmann (eds.), The Retinoids, pp. 319-350. New York: Raven Press, 1994.
24. Chakravarti, D., LaMorte, V. J., Nelson, M. C., Nakajima, T., Schulman, I. G., Juguilion, T., Montminy, M., and Evans, R. M. Role of CBP/P300 in nuclear receptor signaling. Nature (Lond.), 383: 99-103, 1996.
25. Kamei, Y., Xu, L., Heinzel, T., Torchia, J., Kurokawa, R., Gloss, B., Lin, S-C., Heyman, R. A., Rose, D. W., Glass, C. K., and Rosenfeld, M. G. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell, 85: 403-414, 1996.
26. Nicholson, R. C., Mader, S., Nagpal, S., Leid, M., Rochette-Egly, C., and Chambon, P. Negative regulation of the rat stromelysin gene promoter by retinoic acid is mediated by an AP1 binding site. EMBO J., 9: 4443-4454, 1990.
27. Schüle, R., Umesono, K., Mangelsdorf, D. J., Bolado, J., Pike, J. W., and Evans, R. O. Jun-Fos and receptors for vitamins A and D recognize a common response element in the human osteocalcin gene. Cell, 61: 497-504, 1990.
28. Brethois, Y., Katzenellenborgen, J. A., and Katzenellenborgen, B. S. Phenol red in culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc. Natl. Acad. Sci. USA, 83: 2496-2500, 1986.
29. Knudsen, S. M., Tams, J. W., Wulff, B. S., and Fahrenkrug, J. A disulfide bond between conserved cysteines in the extracellular loops of the human VIP receptor is required for binding and activation. FEBS Lett., 412: 141-143, 1997.
30. Akera, T., and Cheng, V. K. A simple method for the determination of affinity and binding site concentration in receptor binding studies. Biochim. Biophys. Acta, 470: 412-423, 1977.
31. Waschek, J. A., Lelievre, V., Bravo, D. T., Nguyen, T., and Muller, J-M. Retinoic acid regulation of the VIP and PACAP autocrine ligand and receptor system in human neuroblastoma cell lines. Peptides (Elmsford), 18: 835-841, 1997.
32. Schroen, D. J., and Brinckerhoff, C. E. Inhibition of rabbit colagenase (Marix Metalloproteinase-1; MMp-1) transcription by retinoid receptor: evidence for binding of RARs/RXRs to the -77 AP-1 site through interactions with c-Jun. J. Cell. Physiol., 169: 320-332, 1996.
33. Lanigan, T. M., Tverberg, L. A., and Russo, A. F. Retinoic acid repression of cell-specific helix-loop-helix-octamer activation of the calcitonin/calcitonin gene-related peptide enhancer. Mol. Cell. Biol., 13: 6079-6088, 1993.
34. Kirfel, J., Kelter, M., Cancela, L. M., Price P. A., and Schüle, R. Identification of a novel negative retinoic acid responsive element in the promoter of the human matrix Gla protein gene. Proc. Natl. Acad. Sci. USA, 94: 2227-2232, 1997.
35. Gespach, C., Bawab, W., Cremoux, P. D., and Calvo, F. Pharmacology, molecular identification, and Functional Characteristics of vasoactive intestinal peptide receptors in human breast cancer cell. Cancer Res., 48: 5079-5083, 1988.
36. Zhao, Z., Zhang, Z-P., Soprano, D. R., and Soprano, K. J. Effect of 9-cis-retinoic acid on growth and RXR expression in human breast cancer cells. Exp. Cell Res., 219: 555-561, 1995.
37. Toma, S., Isnardi, L., Raffo, P., Dastoli, G., de Francisci, E., Riccardi, L., Palumbo, R., and Bollag, W. Effect of all-trans-Retinoic acid and 13-cis-retinoic acid on breast cancer cell lines: growth inhibition and apotosis induction. Int. J. Cancer, 70: 619-627, 1997.
38. Sreedharan, S. P., Huang, J-X., Cheung, M-C., and Goetzl, E. J. Structure, expression and chromosomal localization of the type I human vasoactive intestinal peptide receptor gene. Proc. Natl. Acad. Sci. USA, 92: 2939-2943, 1995.